Spotlight on Oncology
Expert Perspectives on Optimizing Outcomes with the Latest Advances in Small Molecule Inhibitors for Chronic Lymphocytic Leukemia
StartActivity Details
1.0 Contact Hour(s)
Expires: April 11, 2023
Accredited By
Rush University Medical Center
Co-Provided By
Target Audience
This activity is designed to meet the educational needs of community oncologists, hematology/oncologists, oncology nurses and NPs, pharmacists and other healthcare professionals involved in the treatment of patients with chronic lymphocytic leukemia.
Learning Objectives
After completing this program, participants should be able to:
- Utilize testing for prognostic and predictive markers to stratify risk and optimize treatment selection for patients with CLL
- Employ the latest evidence and available guidelines to select among available therapeutic options in the first-line setting or for relapsed/refractory disease, including considerations for optimal sequencing of therapies
- Describe the clinical data regarding efficacy and safety of emerging therapies and approaches for the treatment of patients with CLL
- Outline acute and long-term safety considerations and factors influencing adherence to CLL treatment and evidence-based strategies to manage these considerations
Activity Description
This education activity is designed to provide the healthcare team with the latest developments and critical insights into treating their patients with CLL. This education will support the healthcare professional in his/her practice setting with the essential tools to critically evaluate efficacy, safety, clinical effectiveness, and application.
Statement of Educational Need
With the recent advances in targeted therapies for CLL, the use of approved and investigational agents is anticipated to expand over the coming years. The introduction of new agents and combinations into the clinic have provided additional effective treatment options but have also created uncertainty over differences in patients who may benefit, efficacy of available and emerging agents, optimal sequencing and combinations, and safety among the available agents. To provide optimal patient care, clinicians must be prepared with a comprehensive understanding of the clinical utility of agents that could significantly impact outcomes for patients with CLL.
Faculty
Clinical Research Director, Division of Lymphoma
Dana-Farber Cancer Institute
Associate Professor of Medicine
Harvard Medical School
Boston, MA
Dr. Davids has provided the following disclosure information:
SAB/Consultant/Honoraria: AbbVie, BMS, Genentech, Janssen, Pharmacyclics, TG Therapeutics, Celgene, AstraZeneca, Eli Lilly, MEI Pharma, Merck, Adaptive Biosciences, BeiGene, Ascentage Pharma, Takeda, Aptitude Health, Research to Practice
Research funding: Genentech, Pharmacyclics, TG Therapeutics, MEI Pharma, Surface Oncology, AstraZeneca, Ascentage Pharma, Novartis
Accreditation Statement
In support of improving patient care, Rush University Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physician/Physician Assistant/Nurse Practitioner
Rush University Medical Center designates this enduring activity for a
maximum of one (1.0) AMA PRA Category 1 Credit(s)™.
Physicians/Physician Assistants/Nurse Practitioners should claim only credit
commensurate with the extent of their participation in the activity.
Nurse
Rush University Medical Center designates this enduring activity for a
maximum of one (1.0) nursing contact hour(s).
This activity will fulfill Category 2 contact hour requirements for pharmacology for ANCC-certified advanced practice nurses.
Pharmacist
Rush University Medical Center designates this knowledge-based enduring
activity for a maximum of one (1.0) contact hour(s) for pharmacists.
Proof of participation will be posted to your NABP CPE profile within 4 to 6 weeks to participants who have successfully completed the post-test. Participants must participate in the entire presentation and complete the course evaluation to receive continuing pharmacy education credit.
Instructions for Receiving Credit
In order to receive credit for participating in this program, participants must listen to the program in its entirety and then complete and submit the CE evaluation form at the conclusion of the program.
Statement of Commercial Support
Supported by an educational grant from AbbVie and Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.
Disclaimer Statement/Disclosure of Unlabeled Use
Rush University Medical Center and Plexus Communications ensure balance, independence, objectivity, and scientific rigor in all our educational activities. In accordance with this policy, Rush University Medical Center identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are resolved by Rush University Medical Center to ensure that all scientific research referred to, reported, or used in a continuing education activity conforms to the generally accepted standards of experimental design, data collection, and analysis. Rush University Medical Center is committed to providing its learners with high-quality activities that promote improvements or quality in health care and not the business interest of a commercial interest.
Contact Information for Questions About the Activity
info@plexuscomm.com
Activity Details
1.0 Contact Hour(s)
Expires: April 11, 2023
Accredited By
Rush University Medical Center
Co-Provided By
Target Audience
This activity is designed to meet the educational needs of community oncologists, hematology/oncologists, oncology nurses and NPs, pharmacists and other healthcare professionals involved in the treatment of patients with chronic lymphocytic leukemia.
Learning Objectives
After completing this program, participants should be able to:
- Utilize testing for prognostic and predictive markers to stratify risk and optimize treatment selection for patients with CLL
- Employ the latest evidence and available guidelines to select among available therapeutic options in the first-line setting or for relapsed/refractory disease, including considerations for optimal sequencing of therapies
- Describe the clinical data regarding efficacy and safety of emerging therapies and approaches for the treatment of patients with CLL
- Outline acute and long-term safety considerations and factors influencing adherence to CLL treatment and evidence-based strategies to manage these considerations
Activity Description
This education activity is designed to provide the healthcare team with the latest developments and critical insights into treating their patients with CLL. This education will support the healthcare professional in his/her practice setting with the essential tools to critically evaluate efficacy, safety, clinical effectiveness, and application.
Statement of Educational Need
With the recent advances in targeted therapies for CLL, the use of approved and investigational agents is anticipated to expand over the coming years. The introduction of new agents and combinations into the clinic have provided additional effective treatment options but have also created uncertainty over differences in patients who may benefit, efficacy of available and emerging agents, optimal sequencing and combinations, and safety among the available agents. To provide optimal patient care, clinicians must be prepared with a comprehensive understanding of the clinical utility of agents that could significantly impact outcomes for patients with CLL.
Faculty
Clinical Research Director, Division of Lymphoma
Dana-Farber Cancer Institute
Associate Professor of Medicine
Harvard Medical School
Boston, MA
Dr. Davids has provided the following disclosure information:
SAB/Consultant/Honoraria: AbbVie, BMS, Genentech, Janssen, Pharmacyclics, TG Therapeutics, Celgene, AstraZeneca, Eli Lilly, MEI Pharma, Merck, Adaptive Biosciences, BeiGene, Ascentage Pharma, Takeda, Aptitude Health, Research to Practice
Research funding: Genentech, Pharmacyclics, TG Therapeutics, MEI Pharma, Surface Oncology, AstraZeneca, Ascentage Pharma, Novartis
Accreditation Statement
In support of improving patient care, Rush University Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physician/Physician Assistant/Nurse Practitioner
Rush University Medical Center designates this enduring activity for a
maximum of one (1.0) AMA PRA Category 1 Credit(s)™.
Physicians/Physician Assistants/Nurse Practitioners should claim only credit
commensurate with the extent of their participation in the activity.
Nurse
Rush University Medical Center designates this enduring activity for a
maximum of one (1.0) nursing contact hour(s).
This activity will fulfill Category 2 contact hour requirements for pharmacology for ANCC-certified advanced practice nurses.
Pharmacist
Rush University Medical Center designates this knowledge-based enduring
activity for a maximum of one (1.0) contact hour(s) for pharmacists.
Proof of participation will be posted to your NABP CPE profile within 4 to 6 weeks to participants who have successfully completed the post-test. Participants must participate in the entire presentation and complete the course evaluation to receive continuing pharmacy education credit.
Instructions for Receiving Credit
In order to receive credit for participating in this program, participants must listen to the program in its entirety and then complete and submit the CE evaluation form at the conclusion of the program.
Statement of Commercial Support
Supported by an educational grant from AbbVie and Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.
Disclaimer Statement/Disclosure of Unlabeled Use
Rush University Medical Center and Plexus Communications ensure balance, independence, objectivity, and scientific rigor in all our educational activities. In accordance with this policy, Rush University Medical Center identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are resolved by Rush University Medical Center to ensure that all scientific research referred to, reported, or used in a continuing education activity conforms to the generally accepted standards of experimental design, data collection, and analysis. Rush University Medical Center is committed to providing its learners with high-quality activities that promote improvements or quality in health care and not the business interest of a commercial interest.
Contact Information for Questions About the Activity
info@plexuscomm.com
Oncology Presentations
Identifying Patients at Risk for Advanced NMSC: A Visual Guide
StartActivity Details
0.25 IPCE Credit(s)™
Expires: April 26, 2023
Provided By
RMEI Medical Education, LLC
Target Audience
This activity is intended for dermatology and medical oncology clinicians (MD/DO/NP/PA) involved in the care of patients with nonmelanoma skin cancers (NMSC).
Learning Objectives
Upon completion of this activity, participants should be better able to:
- Employ established approaches for nonmelanoma skin cancer (NMSC) risk stratification and staging to identify patients at high risk for advanced or difficult-to-treat disease
- Integrate the unique roles and responsibilities of the interprofessional care team when managing patients with advanced NMSC
Activity Description
This 15-minute infographic activity uses an interactive approach augmented by whiteboard animations and faculty videos to delineate risk factors for aggressive NMSC, risk stratification and staging methods, and the importance of interprofessional care.
Chair
Director, Melanoma and Renal Cancer Team
Seattle Cancer Care Alliance
Associate Professor, Division of Medical Oncology
University of Washington School of Medicine
Associate Professor, Clinical Research Division
Fred Hutchinson Cancer Research Center
Seattle, WA
Disclosure of Financial Relationships
RMEI Medical Education, LLC (RMEI) requires instructors, planners, managers, and others in control of educational content to disclose all their financial relationships with ineligible companies over the previous 24 months. All identified financial relationships are thoroughly vetted and mitigated according to RMEI policy.
Faculty
Shailender Bhatia, MD, has relevant financial relationships with Bristol Myers Squibb, EMD Serono, Genentech, Regeneron, Sanofi Genzyme (Advisor); 4SC, Amphivena, Bristol Myers Squibb, Checkmate Pharmaceuticals, EMD Serono, Exicure, Immune Design, Merck, NantKwest, Nektar, Novartis, OncoSec, Xencor (Grant/Research Support paid to University of Washington).
All of the relevant financial relationships listed for this individual has been mitigated according to RMEI policies.
Planners and Managers
RMEI Medical Education, LLC planners and managers have no relevant financial
relationship(s) with ineligible companies to disclose.
Joint Accreditation Statement
In support
of improving patient care, RMEI Medical Education, LLC is jointly accredited
by the Accreditation Council for Continuing Medical Education (ACCME), the
Accreditation Council for Pharmacy Education (ACPE), and the American Nurses
Credentialing Center (ANCC), to provide continuing education for the
healthcare team.
Designation of Credit
Physician Continuing Medical Education
RMEI Medical Education, LLC designates this enduring material for a maximum
of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only
the credit commensurate with the extent of their participation in the
activity.
Interprofessional Continuing
Education
This
activity was planned by and for the healthcare team, and learners will
receive 0.25 Interprofessional Continuing Education (IPCE) credit for
learning and change.
Instructions for Receiving Credit
In order to receive credit, participants must review the activity content and successfully complete both the post-test and evaluation. A statement of credit will be available to print immediately. You must score 75% or higher on the post-test to receive credit for this activity. If you have questions about this activity, please contact RMEI at contact@rmei.com.
Users must:
- Read the learning objectives and faculty disclosures
- Participate in the activity
- Complete the activity evaluation and attest to credit
There is no fee for this educational activity.
Your Feedback is Important!
COMPLETE THE EVALUATION FORM
AND YOU WILL BE ENTERED INTO A DRAWING FOR A $100* AMAZON GIFT
CARD!
*The expense for this gift card is solely funded by RMEI Medical Education,
LLC.
No supporter funding was used for the expense of this gift card.
Rules and Regulations
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a jointly
accredited provider. The winner will be selected via automated random drawing
on a quarterly basis from among all eligible entries and notified through the
contact information provided. In accordance with our privacy policy, we do
not share your information with any third parties. By entering the
sweepstakes, you grant RMEI permission to use your e-mail address to reach
you for notification and prize fulfillment. Only individuals who complete the
evaluation forms and provide contact information will be eligible to win.
Open to those who have a US postal address and who are 18 years or older.
Only one prize per person and per household will be awarded. The prize will
be a $100 Amazon gift card.
Statement of Commercial Support
This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc and Sanofi Genzyme.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Activity Details
0.25 IPCE Credit(s)™
Expires: April 26, 2023
Provided By
RMEI Medical Education, LLC
Target Audience
This activity is intended for dermatology and medical oncology clinicians (MD/DO/NP/PA) involved in the care of patients with nonmelanoma skin cancers (NMSC).
Learning Objectives
Upon completion of this activity, participants should be better able to:
- Employ established approaches for nonmelanoma skin cancer (NMSC) risk stratification and staging to identify patients at high risk for advanced or difficult-to-treat disease
- Integrate the unique roles and responsibilities of the interprofessional care team when managing patients with advanced NMSC
Activity Description
This 15-minute infographic activity uses an interactive approach augmented by whiteboard animations and faculty videos to delineate risk factors for aggressive NMSC, risk stratification and staging methods, and the importance of interprofessional care.
Chair
Director, Melanoma and Renal Cancer Team
Seattle Cancer Care Alliance
Associate Professor, Division of Medical Oncology
University of Washington School of Medicine
Associate Professor, Clinical Research Division
Fred Hutchinson Cancer Research Center
Seattle, WA
Disclosure of Financial Relationships
RMEI Medical Education, LLC (RMEI) requires instructors, planners, managers, and others in control of educational content to disclose all their financial relationships with ineligible companies over the previous 24 months. All identified financial relationships are thoroughly vetted and mitigated according to RMEI policy.
Faculty
Shailender Bhatia, MD, has relevant financial relationships with Bristol Myers Squibb, EMD Serono, Genentech, Regeneron, Sanofi Genzyme (Advisor); 4SC, Amphivena, Bristol Myers Squibb, Checkmate Pharmaceuticals, EMD Serono, Exicure, Immune Design, Merck, NantKwest, Nektar, Novartis, OncoSec, Xencor (Grant/Research Support paid to University of Washington).
All of the relevant financial relationships listed for this individual has been mitigated according to RMEI policies.
Planners and Managers
RMEI Medical Education, LLC planners and managers have no relevant financial
relationship(s) with ineligible companies to disclose.
Joint Accreditation Statement
In support
of improving patient care, RMEI Medical Education, LLC is jointly accredited
by the Accreditation Council for Continuing Medical Education (ACCME), the
Accreditation Council for Pharmacy Education (ACPE), and the American Nurses
Credentialing Center (ANCC), to provide continuing education for the
healthcare team.
Designation of Credit
Physician Continuing Medical Education
RMEI Medical Education, LLC designates this enduring material for a maximum
of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only
the credit commensurate with the extent of their participation in the
activity.
Interprofessional Continuing
Education
This
activity was planned by and for the healthcare team, and learners will
receive 0.25 Interprofessional Continuing Education (IPCE) credit for
learning and change.
Instructions for Receiving Credit
In order to receive credit, participants must review the activity content and successfully complete both the post-test and evaluation. A statement of credit will be available to print immediately. You must score 75% or higher on the post-test to receive credit for this activity. If you have questions about this activity, please contact RMEI at contact@rmei.com.
Users must:
- Read the learning objectives and faculty disclosures
- Participate in the activity
- Complete the activity evaluation and attest to credit
There is no fee for this educational activity.
Your Feedback is Important!
COMPLETE THE EVALUATION FORM
AND YOU WILL BE ENTERED INTO A DRAWING FOR A $100* AMAZON GIFT
CARD!
*The expense for this gift card is solely funded by RMEI Medical Education,
LLC.
No supporter funding was used for the expense of this gift card.
Rules and Regulations
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a jointly
accredited provider. The winner will be selected via automated random drawing
on a quarterly basis from among all eligible entries and notified through the
contact information provided. In accordance with our privacy policy, we do
not share your information with any third parties. By entering the
sweepstakes, you grant RMEI permission to use your e-mail address to reach
you for notification and prize fulfillment. Only individuals who complete the
evaluation forms and provide contact information will be eligible to win.
Open to those who have a US postal address and who are 18 years or older.
Only one prize per person and per household will be awarded. The prize will
be a $100 Amazon gift card.
Statement of Commercial Support
This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc and Sanofi Genzyme.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Expert Perspectives on Optimizing Outcomes with the Latest Advances in Small Molecule Inhibitors for Chronic Lymphocytic Leukemia
StartActivity Details
1.0 Contact Hour(s)
Expires: April 11, 2023
Accredited By
Rush University Medical Center
Co-Provided By
Target Audience
This activity is designed to meet the educational needs of community oncologists, hematology/oncologists, oncology nurses and NPs, pharmacists and other healthcare professionals involved in the treatment of patients with chronic lymphocytic leukemia.
Learning Objectives
After completing this program, participants should be able to:
- Utilize testing for prognostic and predictive markers to stratify risk and optimize treatment selection for patients with CLL
- Employ the latest evidence and available guidelines to select among available therapeutic options in the first-line setting or for relapsed/refractory disease, including considerations for optimal sequencing of therapies
- Describe the clinical data regarding efficacy and safety of emerging therapies and approaches for the treatment of patients with CLL
- Outline acute and long-term safety considerations and factors influencing adherence to CLL treatment and evidence-based strategies to manage these considerations
Activity Description
This education activity is designed to provide the healthcare team with the latest developments and critical insights into treating their patients with CLL. This education will support the healthcare professional in his/her practice setting with the essential tools to critically evaluate efficacy, safety, clinical effectiveness, and application.
Statement of Educational Need
With the recent advances in targeted therapies for CLL, the use of approved and investigational agents is anticipated to expand over the coming years. The introduction of new agents and combinations into the clinic have provided additional effective treatment options but have also created uncertainty over differences in patients who may benefit, efficacy of available and emerging agents, optimal sequencing and combinations, and safety among the available agents. To provide optimal patient care, clinicians must be prepared with a comprehensive understanding of the clinical utility of agents that could significantly impact outcomes for patients with CLL.
Faculty
Clinical Research Director, Division of Lymphoma
Dana-Farber Cancer Institute
Associate Professor of Medicine
Harvard Medical School
Boston, MA
Dr. Davids has provided the following disclosure information:
SAB/Consultant/Honoraria: AbbVie, BMS, Genentech, Janssen, Pharmacyclics, TG Therapeutics, Celgene, AstraZeneca, Eli Lilly, MEI Pharma, Merck, Adaptive Biosciences, BeiGene, Ascentage Pharma, Takeda, Aptitude Health, Research to Practice
Research funding: Genentech, Pharmacyclics, TG Therapeutics, MEI Pharma, Surface Oncology, AstraZeneca, Ascentage Pharma, Novartis
Accreditation Statement
In support of improving patient care, Rush University Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physician/Physician Assistant/Nurse Practitioner
Rush University Medical Center designates this enduring activity for a
maximum of one (1.0) AMA PRA Category 1 Credit(s)™.
Physicians/Physician Assistants/Nurse Practitioners should claim only credit
commensurate with the extent of their participation in the activity.
Nurse
Rush University Medical Center designates this enduring activity for a
maximum of one (1.0) nursing contact hour(s).
This activity will fulfill Category 2 contact hour requirements for pharmacology for ANCC-certified advanced practice nurses.
Pharmacist
Rush University Medical Center designates this knowledge-based enduring
activity for a maximum of one (1.0) contact hour(s) for pharmacists.
Proof of participation will be posted to your NABP CPE profile within 4 to 6 weeks to participants who have successfully completed the post-test. Participants must participate in the entire presentation and complete the course evaluation to receive continuing pharmacy education credit.
Instructions for Receiving Credit
In order to receive credit for participating in this program, participants must listen to the program in its entirety and then complete and submit the CE evaluation form at the conclusion of the program.
Statement of Commercial Support
Supported by an educational grant from AbbVie and Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.
Disclaimer Statement/Disclosure of Unlabeled Use
Rush University Medical Center and Plexus Communications ensure balance, independence, objectivity, and scientific rigor in all our educational activities. In accordance with this policy, Rush University Medical Center identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are resolved by Rush University Medical Center to ensure that all scientific research referred to, reported, or used in a continuing education activity conforms to the generally accepted standards of experimental design, data collection, and analysis. Rush University Medical Center is committed to providing its learners with high-quality activities that promote improvements or quality in health care and not the business interest of a commercial interest.
Contact Information for Questions About the Activity
info@plexuscomm.com
Activity Details
1.0 Contact Hour(s)
Expires: April 11, 2023
Accredited By
Rush University Medical Center
Co-Provided By
Target Audience
This activity is designed to meet the educational needs of community oncologists, hematology/oncologists, oncology nurses and NPs, pharmacists and other healthcare professionals involved in the treatment of patients with chronic lymphocytic leukemia.
Learning Objectives
After completing this program, participants should be able to:
- Utilize testing for prognostic and predictive markers to stratify risk and optimize treatment selection for patients with CLL
- Employ the latest evidence and available guidelines to select among available therapeutic options in the first-line setting or for relapsed/refractory disease, including considerations for optimal sequencing of therapies
- Describe the clinical data regarding efficacy and safety of emerging therapies and approaches for the treatment of patients with CLL
- Outline acute and long-term safety considerations and factors influencing adherence to CLL treatment and evidence-based strategies to manage these considerations
Activity Description
This education activity is designed to provide the healthcare team with the latest developments and critical insights into treating their patients with CLL. This education will support the healthcare professional in his/her practice setting with the essential tools to critically evaluate efficacy, safety, clinical effectiveness, and application.
Statement of Educational Need
With the recent advances in targeted therapies for CLL, the use of approved and investigational agents is anticipated to expand over the coming years. The introduction of new agents and combinations into the clinic have provided additional effective treatment options but have also created uncertainty over differences in patients who may benefit, efficacy of available and emerging agents, optimal sequencing and combinations, and safety among the available agents. To provide optimal patient care, clinicians must be prepared with a comprehensive understanding of the clinical utility of agents that could significantly impact outcomes for patients with CLL.
Faculty
Clinical Research Director, Division of Lymphoma
Dana-Farber Cancer Institute
Associate Professor of Medicine
Harvard Medical School
Boston, MA
Dr. Davids has provided the following disclosure information:
SAB/Consultant/Honoraria: AbbVie, BMS, Genentech, Janssen, Pharmacyclics, TG Therapeutics, Celgene, AstraZeneca, Eli Lilly, MEI Pharma, Merck, Adaptive Biosciences, BeiGene, Ascentage Pharma, Takeda, Aptitude Health, Research to Practice
Research funding: Genentech, Pharmacyclics, TG Therapeutics, MEI Pharma, Surface Oncology, AstraZeneca, Ascentage Pharma, Novartis
Accreditation Statement
In support of improving patient care, Rush University Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physician/Physician Assistant/Nurse Practitioner
Rush University Medical Center designates this enduring activity for a
maximum of one (1.0) AMA PRA Category 1 Credit(s)™.
Physicians/Physician Assistants/Nurse Practitioners should claim only credit
commensurate with the extent of their participation in the activity.
Nurse
Rush University Medical Center designates this enduring activity for a
maximum of one (1.0) nursing contact hour(s).
This activity will fulfill Category 2 contact hour requirements for pharmacology for ANCC-certified advanced practice nurses.
Pharmacist
Rush University Medical Center designates this knowledge-based enduring
activity for a maximum of one (1.0) contact hour(s) for pharmacists.
Proof of participation will be posted to your NABP CPE profile within 4 to 6 weeks to participants who have successfully completed the post-test. Participants must participate in the entire presentation and complete the course evaluation to receive continuing pharmacy education credit.
Instructions for Receiving Credit
In order to receive credit for participating in this program, participants must listen to the program in its entirety and then complete and submit the CE evaluation form at the conclusion of the program.
Statement of Commercial Support
Supported by an educational grant from AbbVie and Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.
Disclaimer Statement/Disclosure of Unlabeled Use
Rush University Medical Center and Plexus Communications ensure balance, independence, objectivity, and scientific rigor in all our educational activities. In accordance with this policy, Rush University Medical Center identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are resolved by Rush University Medical Center to ensure that all scientific research referred to, reported, or used in a continuing education activity conforms to the generally accepted standards of experimental design, data collection, and analysis. Rush University Medical Center is committed to providing its learners with high-quality activities that promote improvements or quality in health care and not the business interest of a commercial interest.
Contact Information for Questions About the Activity
info@plexuscomm.com
Advanced NMSC: Determining Patient Candidacy for Immunotherapy
StartActivity Details
0.25 IPCE Credit(s)™
Expires: April 5, 2023
Provided By
RMEI Medical Education, LLC
Target Audience
This activity is intended for dermatology and medical oncology clinicians (MD/DO/NP/PA) involved in the care of patients with nonmelanoma skin cancers (NMSC).
Learning Objectives
Upon completion of this activity, participants should be better able to:
- Identify patients with advanced nonmelanoma skin cancer (NMSC) who are ideal candidates for treatment with immunotherapy
- Integrate the unique roles and responsibilities of the interprofessional care team when managing patients with advanced NMSC
Activity Description
This activity features an interprofessional, multidisciplinary panel of experts offering privileged insights on assessing patient candidacy for immunotherapy in advanced cutaneous squamous cell carcinoma (CSCC) and basal cell carcinoma (BCC). The discussion is augmented by case studies highlighting key aspects of risk stratification, staging, and management.
Chair
Director, Melanoma and Renal Cancer Team
Seattle Cancer Care Alliance
Associate Professor, Division of Medical Oncology
University of Washington School of Medicine
Associate Professor, Clinical Research Division
Fred Hutchinson Cancer Research Center
Seattle, WA
Faculty
Physician Assistant, Seattle Cancer Care Alliance
Teaching Associate, University of Washington School of Medicine
Physician Assistant, UW Medicine
Seattle, WA
Academic Director, Mohs Dermatologic Surgery Center
Director, Dana Farber High Risk Cancer Clinic
Assistant Professor, Dermatology, Harvard Medical School
Department of Dermatology Brigham and Women's Faulkner Hospital
Boston, MA
Disclosure of Financial Relationships
RMEI Medical Education, LLC (RMEI) requires instructors, planners, managers, and others in control of educational content to disclose all their financial relationships with ineligible companies over the previous 24 months. All identified financial relationships are thoroughly vetted and mitigated according to RMEI policy.
Faculty
Shailender Bhatia, MD, has relevant financial relationships with Bristol Myers Squibb, EMD Serono, Genentech, Regeneron, Sanofi Genzyme (Advisor); 4SC, Amphivena, Bristol Myers Squibb, Checkmate Pharmaceuticals, EMD Serono, Exicure, Immune Design, Merck, NantKwest, Nektar, Novartis, OncoSec, Xencor (Grant/Research Support paid to University of Washington).
Coley J. Doolittle-Amieva, MCMSc, PA-C, has no relevant financial relationships with ineligible companies to disclose.
Emily S. Ruiz, MD, PhD, has relevant financial relationships with Checkpoint Therapeutics, Leo Pharma, Pellepharma, Regeneron (Consultant).
All of the relevant financial relationships listed for these individuals have been mitigated according to RMEI policies.
Planners and Managers
RMEI Medical Education, LLC planners and managers have no relevant financial
relationship(s) with ineligible companies to disclose.
Joint Accreditation Statement
In support
of improving patient care, RMEI Medical Education, LLC is jointly accredited
by the Accreditation Council for Continuing Medical Education (ACCME), the
Accreditation Council for Pharmacy Education (ACPE), and the American Nurses
Credentialing Center (ANCC), to provide continuing education for the
healthcare team.
Designation of Credit
Physician Continuing Medical Education
RMEI Medical Education, LLC designates this enduring material for a maximum
of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only
the credit commensurate with the extent of their participation in the
activity.
Interprofessional Continuing
Education
This
activity was planned by and for the healthcare team, and learners will
receive 0.25 Interprofessional Continuing Education (IPCE) credit for
learning and change.
Instructions for Receiving Credit
In order to receive credit, participants must review the activity content and successfully complete both the post-test and evaluation. A statement of credit will be available to print immediately. You must score 75% or higher on the post-test to receive credit for this activity. If you have questions about this activity, please contact RMEI at contact@rmei.com.
Users must:
- Read the learning objectives and faculty disclosures
- Participate in the activity
- Complete the activity evaluation and attest to credit
There is no fee for this educational activity.
Your Feedback is Important!
COMPLETE THE EVALUATION FORM
AND YOU WILL BE ENTERED INTO A DRAWING FOR A $100* AMAZON GIFT
CARD!
*The expense for this gift card is solely funded by RMEI Medical Education,
LLC.
No supporter funding was used for the expense of this gift card.
Rules and Regulations
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a jointly
accredited provider. The winner will be selected via automated random drawing
on a quarterly basis from among all eligible entries and notified through the
contact information provided. In accordance with our privacy policy, we do
not share your information with any third parties. By entering the
sweepstakes, you grant RMEI permission to use your e-mail address to reach
you for notification and prize fulfillment. Only individuals who complete the
evaluation forms and provide contact information will be eligible to win.
Open to those who have a US postal address and who are 18 years or older.
Only one prize per person and per household will be awarded. The prize will
be a $100 Amazon gift card.
Statement of Commercial Support
This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc and Sanofi Genzyme.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.
Activity Details
0.25 IPCE Credit(s)™
Expires: April 5, 2023
Provided By
RMEI Medical Education, LLC
Target Audience
This activity is intended for dermatology and medical oncology clinicians (MD/DO/NP/PA) involved in the care of patients with nonmelanoma skin cancers (NMSC).
Learning Objectives
Upon completion of this activity, participants should be better able to:
- Identify patients with advanced nonmelanoma skin cancer (NMSC) who are ideal candidates for treatment with immunotherapy
- Integrate the unique roles and responsibilities of the interprofessional care team when managing patients with advanced NMSC
Activity Description
This activity features an interprofessional, multidisciplinary panel of experts offering privileged insights on assessing patient candidacy for immunotherapy in advanced cutaneous squamous cell carcinoma (CSCC) and basal cell carcinoma (BCC). The discussion is augmented by case studies highlighting key aspects of risk stratification, staging, and management.
Chair
Director, Melanoma and Renal Cancer Team
Seattle Cancer Care Alliance
Associate Professor, Division of Medical Oncology
University of Washington School of Medicine
Associate Professor, Clinical Research Division
Fred Hutchinson Cancer Research Center
Seattle, WA
Faculty
Physician Assistant, Seattle Cancer Care Alliance
Teaching Associate, University of Washington School of Medicine
Physician Assistant, UW Medicine
Seattle, WA
Academic Director, Mohs Dermatologic Surgery Center
Director, Dana Farber High Risk Cancer Clinic
Assistant Professor, Dermatology, Harvard Medical School
Department of Dermatology Brigham and Women's Faulkner Hospital
Boston, MA
Disclosure of Financial Relationships
RMEI Medical Education, LLC (RMEI) requires instructors, planners, managers, and others in control of educational content to disclose all their financial relationships with ineligible companies over the previous 24 months. All identified financial relationships are thoroughly vetted and mitigated according to RMEI policy.
Faculty
Shailender Bhatia, MD, has relevant financial relationships with Bristol Myers Squibb, EMD Serono, Genentech, Regeneron, Sanofi Genzyme (Advisor); 4SC, Amphivena, Bristol Myers Squibb, Checkmate Pharmaceuticals, EMD Serono, Exicure, Immune Design, Merck, NantKwest, Nektar, Novartis, OncoSec, Xencor (Grant/Research Support paid to University of Washington).
Coley J. Doolittle-Amieva, MCMSc, PA-C, has no relevant financial relationships with ineligible companies to disclose.
Emily S. Ruiz, MD, PhD, has relevant financial relationships with Checkpoint Therapeutics, Leo Pharma, Pellepharma, Regeneron (Consultant).
All of the relevant financial relationships listed for these individuals have been mitigated according to RMEI policies.
Planners and Managers
RMEI Medical Education, LLC planners and managers have no relevant financial
relationship(s) with ineligible companies to disclose.
Joint Accreditation Statement
In support
of improving patient care, RMEI Medical Education, LLC is jointly accredited
by the Accreditation Council for Continuing Medical Education (ACCME), the
Accreditation Council for Pharmacy Education (ACPE), and the American Nurses
Credentialing Center (ANCC), to provide continuing education for the
healthcare team.
Designation of Credit
Physician Continuing Medical Education
RMEI Medical Education, LLC designates this enduring material for a maximum
of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only
the credit commensurate with the extent of their participation in the
activity.
Interprofessional Continuing
Education
This
activity was planned by and for the healthcare team, and learners will
receive 0.25 Interprofessional Continuing Education (IPCE) credit for
learning and change.
Instructions for Receiving Credit
In order to receive credit, participants must review the activity content and successfully complete both the post-test and evaluation. A statement of credit will be available to print immediately. You must score 75% or higher on the post-test to receive credit for this activity. If you have questions about this activity, please contact RMEI at contact@rmei.com.
Users must:
- Read the learning objectives and faculty disclosures
- Participate in the activity
- Complete the activity evaluation and attest to credit
There is no fee for this educational activity.
Your Feedback is Important!
COMPLETE THE EVALUATION FORM
AND YOU WILL BE ENTERED INTO A DRAWING FOR A $100* AMAZON GIFT
CARD!
*The expense for this gift card is solely funded by RMEI Medical Education,
LLC.
No supporter funding was used for the expense of this gift card.
Rules and Regulations
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a jointly
accredited provider. The winner will be selected via automated random drawing
on a quarterly basis from among all eligible entries and notified through the
contact information provided. In accordance with our privacy policy, we do
not share your information with any third parties. By entering the
sweepstakes, you grant RMEI permission to use your e-mail address to reach
you for notification and prize fulfillment. Only individuals who complete the
evaluation forms and provide contact information will be eligible to win.
Open to those who have a US postal address and who are 18 years or older.
Only one prize per person and per household will be awarded. The prize will
be a $100 Amazon gift card.
Statement of Commercial Support
This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc and Sanofi Genzyme.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.
Immunotherapy in Advanced NMSC: Treatment Selection and Collaborative Care
StartActivity Details
0.25 IPCE Credit(s)™
Expires: April 5, 2023
Provided By
RMEI Medical Education, LLC
Target Audience
This activity is intended for dermatology and medical oncology clinicians (MD/DO/NP/PA) involved in the care of patients with nonmelanoma skin cancers (NMSC).
Learning Objectives
Upon completion of this activity, participants should be better able to:
- Select appropriate immunotherapy for patients with advanced nonmelanoma skin cancer (NMSC) based on current safety and efficacy data
- Integrate the unique roles and responsibilities of the interprofessional care team when managing patients with advanced NMSC
Activity Description
This activity features an interprofessional, multidisciplinary panel of experts offering privileged insights on evidence-based immunotherapy selection and collaborative care in advanced cutaneous squamous cell carcinoma (CSCC) and basal cell carcinoma (BCC).
Chair
Director, Cutaneous Oncology, GW Cancer Center
Director, Dermatologic Surgery, GW Department of Dermatology
Assistant Professor, Dermatology & Hematology/Oncology
Washington, DC
Faculty
Medical Oncologist, Dermatologist
Massachusetts General Hospital
Director, Center for Merkel Cell Carcinoma
Co-Director, NMSC Multi-Disciplinary Clinic
Department of Medicine, Division of Hematology/Oncology
Department of Dermatology
Massachusetts General Cancer Center
Boston, MA
Nurse Practitioner, Center for Melanoma
Massachusetts General Hospital
Boston, MA
Disclosure of Financial Relationships
RMEI Medical Education, LLC (RMEI) requires instructors, planners, managers, and others in control of educational content to disclose all their financial relationships with ineligible companies over the previous 24 months. All identified financial relationships are thoroughly vetted and mitigated according to RMEI policy.
Faculty
Vishal Anil Patel, MD, FAAD, FACMS, has relevant financial relationships with Lazarus AI, Science 37 (Stock/Shareholder); Regeneron, Sanofi (Speaker/Speaker’s Bureau); Almirall, Jounce Therapeutics, PhD Biosciences, Regeneron (Consultant); Almirall, Regeneron, Sanofi (Advisor).
David M. Miller, MD, PhD, FAAD, has relevant financial relationships with Checkpoint Therapeutics (Stock/Shareholder); Castle Biosciences, Checkpoint Therapeutics, EMD Serono, Merck KGaA, Merck Sharpe & Dome, Pfizer, Regeneron, Sanofi Genzyme (Advisory/Consultant); Kartos Therapeutics, NeoImmuneTech, Regeneron (Grants/Research Support).
Krista M. Rubin, MS, RN, FNP-BC, has relevant financial relationships with BMS, Eisai, Merck (Advisor).
All of the relevant financial relationships listed for these individuals have been mitigated according to RMEI policies.
Planners and Managers
RMEI Medical Education, LLC planners and managers have no relevant financial
relationship(s) with ineligible companies to disclose.
Joint Accreditation Statement
In support
of improving patient care, RMEI Medical Education, LLC is jointly accredited
by the Accreditation Council for Continuing Medical Education (ACCME), the
Accreditation Council for Pharmacy Education (ACPE), and the American Nurses
Credentialing Center (ANCC), to provide continuing education for the
healthcare team.
Designation of Credit
Physician Continuing Medical Education
RMEI Medical Education, LLC designates this enduring material for a maximum
of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only
the credit commensurate with the extent of their participation in the
activity.
Interprofessional Continuing
Education
This
activity was planned by and for the healthcare team, and learners will
receive 0.25 Interprofessional Continuing Education (IPCE) credit for
learning and change.
Instructions for Receiving Credit
In order to receive credit, participants must review the activity content and successfully complete both the post-test and evaluation. A statement of credit will be available to print immediately. You must score 75% or higher on the post-test to receive credit for this activity. If you have questions about this activity, please contact RMEI at contact@rmei.com.
Users must:
- Read the learning objectives and faculty disclosures
- Participate in the activity
- Complete the activity evaluation and attest to credit
There is no fee for this educational activity.
Your Feedback is Important!
COMPLETE THE EVALUATION FORM
AND YOU WILL BE ENTERED INTO A DRAWING FOR A $100* AMAZON GIFT
CARD!
*The expense for this gift card is solely funded by RMEI Medical Education,
LLC.
No supporter funding was used for the expense of this gift card.
Rules and Regulations
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a jointly
accredited provider. The winner will be selected via automated random drawing
on a quarterly basis from among all eligible entries and notified through the
contact information provided. In accordance with our privacy policy, we do
not share your information with any third parties. By entering the
sweepstakes, you grant RMEI permission to use your e-mail address to reach
you for notification and prize fulfillment. Only individuals who complete the
evaluation forms and provide contact information will be eligible to win.
Open to those who have a US postal address and who are 18 years or older.
Only one prize per person and per household will be awarded. The prize will
be a $100 Amazon gift card.
Statement of Commercial Support
This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc and Sanofi Genzyme.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.
Activity Details
0.25 IPCE Credit(s)™
Expires: April 5, 2023
Provided By
RMEI Medical Education, LLC
Target Audience
This activity is intended for dermatology and medical oncology clinicians (MD/DO/NP/PA) involved in the care of patients with nonmelanoma skin cancers (NMSC).
Learning Objectives
Upon completion of this activity, participants should be better able to:
- Select appropriate immunotherapy for patients with advanced nonmelanoma skin cancer (NMSC) based on current safety and efficacy data
- Integrate the unique roles and responsibilities of the interprofessional care team when managing patients with advanced NMSC
Activity Description
This activity features an interprofessional, multidisciplinary panel of experts offering privileged insights on evidence-based immunotherapy selection and collaborative care in advanced cutaneous squamous cell carcinoma (CSCC) and basal cell carcinoma (BCC).
Chair
Director, Cutaneous Oncology, GW Cancer Center
Director, Dermatologic Surgery, GW Department of Dermatology
Assistant Professor, Dermatology & Hematology/Oncology
Washington, DC
Faculty
Medical Oncologist, Dermatologist
Massachusetts General Hospital
Director, Center for Merkel Cell Carcinoma
Co-Director, NMSC Multi-Disciplinary Clinic
Department of Medicine, Division of Hematology/Oncology
Department of Dermatology
Massachusetts General Cancer Center
Boston, MA
Nurse Practitioner, Center for Melanoma
Massachusetts General Hospital
Boston, MA
Disclosure of Financial Relationships
RMEI Medical Education, LLC (RMEI) requires instructors, planners, managers, and others in control of educational content to disclose all their financial relationships with ineligible companies over the previous 24 months. All identified financial relationships are thoroughly vetted and mitigated according to RMEI policy.
Faculty
Vishal Anil Patel, MD, FAAD, FACMS, has relevant financial relationships with Lazarus AI, Science 37 (Stock/Shareholder); Regeneron, Sanofi (Speaker/Speaker’s Bureau); Almirall, Jounce Therapeutics, PhD Biosciences, Regeneron (Consultant); Almirall, Regeneron, Sanofi (Advisor).
David M. Miller, MD, PhD, FAAD, has relevant financial relationships with Checkpoint Therapeutics (Stock/Shareholder); Castle Biosciences, Checkpoint Therapeutics, EMD Serono, Merck KGaA, Merck Sharpe & Dome, Pfizer, Regeneron, Sanofi Genzyme (Advisory/Consultant); Kartos Therapeutics, NeoImmuneTech, Regeneron (Grants/Research Support).
Krista M. Rubin, MS, RN, FNP-BC, has relevant financial relationships with BMS, Eisai, Merck (Advisor).
All of the relevant financial relationships listed for these individuals have been mitigated according to RMEI policies.
Planners and Managers
RMEI Medical Education, LLC planners and managers have no relevant financial
relationship(s) with ineligible companies to disclose.
Joint Accreditation Statement
In support
of improving patient care, RMEI Medical Education, LLC is jointly accredited
by the Accreditation Council for Continuing Medical Education (ACCME), the
Accreditation Council for Pharmacy Education (ACPE), and the American Nurses
Credentialing Center (ANCC), to provide continuing education for the
healthcare team.
Designation of Credit
Physician Continuing Medical Education
RMEI Medical Education, LLC designates this enduring material for a maximum
of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only
the credit commensurate with the extent of their participation in the
activity.
Interprofessional Continuing
Education
This
activity was planned by and for the healthcare team, and learners will
receive 0.25 Interprofessional Continuing Education (IPCE) credit for
learning and change.
Instructions for Receiving Credit
In order to receive credit, participants must review the activity content and successfully complete both the post-test and evaluation. A statement of credit will be available to print immediately. You must score 75% or higher on the post-test to receive credit for this activity. If you have questions about this activity, please contact RMEI at contact@rmei.com.
Users must:
- Read the learning objectives and faculty disclosures
- Participate in the activity
- Complete the activity evaluation and attest to credit
There is no fee for this educational activity.
Your Feedback is Important!
COMPLETE THE EVALUATION FORM
AND YOU WILL BE ENTERED INTO A DRAWING FOR A $100* AMAZON GIFT
CARD!
*The expense for this gift card is solely funded by RMEI Medical Education,
LLC.
No supporter funding was used for the expense of this gift card.
Rules and Regulations
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a jointly
accredited provider. The winner will be selected via automated random drawing
on a quarterly basis from among all eligible entries and notified through the
contact information provided. In accordance with our privacy policy, we do
not share your information with any third parties. By entering the
sweepstakes, you grant RMEI permission to use your e-mail address to reach
you for notification and prize fulfillment. Only individuals who complete the
evaluation forms and provide contact information will be eligible to win.
Open to those who have a US postal address and who are 18 years or older.
Only one prize per person and per household will be awarded. The prize will
be a $100 Amazon gift card.
Statement of Commercial Support
This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc and Sanofi Genzyme.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.
TROP2 in Non-Small Cell Lung Cancer: A Novel Therapeutic Target
StartActivity Details
1.0 ABPath CC Point(s)
Expires: March 30, 2023
Accredited By
This continuing medical education activity is provided by
Target Audience
The intended audience for the activity is oncologists, pathologists, oncology nurse practitioners, oncology physician assistants, and other health care professionals involved in the management of patients with non-small cell lung cancer (NSCLC).
Learning Objectives
Upon successful completion of the activity, participants should be better able to:
- Review the role of trophoblast cell surface antigen 2 (TROP2) in tumor biology as well as its implications as a cancer biomarker.
- Describe how novel antibody drug conjugates exploit TROP2 as an anticancer therapy.
- Examine current unmet needs for patients with NSCLC without actionable mutations.
- Assess the latest clinical safety and efficacy regarding new and emerging TROP2 antibody drug conjugates for the management of patients with NSCLC who have progressed on prior treatment.
Activity Description
For patients with non-small cell lung cancer (NSCLC) who do not have actionable genomic alterations, programmed death ligand 1 immunotherapy, with or without platinum-based chemotherapy, is the standard of care. These regimens have demonstrated clear clinical benefit, yet 40% to 60% of patients do not respond to these initial therapies, or eventually experience disease progression. Options are limited for these patients, but novel therapies, such as antibody drug conjugates that target trophoblast cell surface antigen 2 (TROP2), are currently under clinical investigation. TROP2 is expressed in approximately 70% of NSCLC tumors, and expression has been associated with poor outcomes. In this continuing medical education activity, experts in the field will review current unmet needs for patients with NSCLC without actionable mutations, discuss the role of TROP2 in tumor biology and its implications as a cancer biomarker, and assess the most recent clinical safety and efficacy data regarding new and emerging TROP2 antibody drug conjugates for the management of patients with NSCLC who have progressed on prior therapies.
Topic
- Introduction
- TROP2: Role in Tumor Biology and Implications for Biomarker (Jacob Sands, MD)
- Second-line Therapy for Patients With Non-Small Cell Lung Cancer: Unmet Needs (Benjamin P. Levy, MD)
- Advances in TROP2-Targeted Therapies for Patients With Non-Small Cell Lung Cancer (Rebecca Heist, MD)
- Conclusion by Activity Chair
Activity Chair
Physician, Dana-Farber Cancer Institute
Instructor of Medicine, Harvard Medical School
Boston, MA
Disclosure:
Consultant: AstraZeneca, Boehringer Ingelheim, Jazz Pharmaceuticals, Lilly, Takeda
Faculty
Associate Professor of Medicine
Harvard Medical School
Massachusetts General Hospital
Boston, MA
Disclosure:
Consultant: AbbVie, Daichii Sankyo, EMD Serono, Novartis
Independent Research Contractor (paid to institution): AbbVie, Agios, Corvus, Daichii Sankyo, Exelixis, Lilly, Mirati, Novartis, Turning Point
Associate Professor
Johns Hopkins School of Medicine
Washington, DC
Disclosure:
Consultant: AstraZeneca, Bristol Myers Squibb, Daiichi Sankyo, Janssen, Lilly, Merck, Pfizer
Reviewer
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.
Vindico Medical Education Staff
Disclosure: No relevant financial relationships to disclose.
Signed Disclosures are on file at Vindico Medical Education, Office
of Medical Affairs and Compliance.
Conflict of Interest Policy/Disclosure Statement
Vindico Medical Education adheres to the Accreditation Council for Continuing Medical Education’s (ACCME) Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers, or others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Accreditation Statement
Vindico Medical Education is accredited by the ACCME to provide continuing medical education for physicians.
Designation of Credit
Vindico Medical Education designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Successful
completion of this CME activity, which includes participation in the
evaluation component, enables the learner to satisfy the Lifelong Learning
requirements for the American Board of Pathology’s (ABPath) Continuing
Certification program and earn up to 1.0 CC points. It is the CME activity
provider’s responsibility to submit learner completion information to ACCME
for the purpose of granting Continuing Certification credit within
approximately 30 days.
Nurse practitioners can apply for AMA PRA Category 1 Credit(s)™ through the American Academy of Nurse Practitioners Certification Board (AANPCB). AANPCB will accept AMA PRA Category 1 Credit(s)™ from organizations accredited by ACCME.
American Academy of Physician Assistants (AAPA) accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit(s)™ from organizations accredited by the ACCME. Physician assistants may receive a maximum of 1.0 hours credit for completing this program.
This enduring material is approved for 1 year from the date of original release, March 31, 2022, to March 30, 2023.
Instructions for Receiving Credit
To participate in this CME activity, you must read the objectives, answer the pretest questions, view the CME content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 75% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.
Statement of Commercial Support
This activity is supported by an educational grant from Daiichi Sankyo, Inc.
Disclaimer Statement/Disclosure of Unlabeled Use
The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)–approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.
Copyright Statement
Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2022 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.
CME Questions?
Contact us at CME@VindicoCME.com
Activity Details
1.0 ABPath CC Point(s)
Expires: March 30, 2023
Accredited By
This continuing medical education activity is provided by
Target Audience
The intended audience for the activity is oncologists, pathologists, oncology nurse practitioners, oncology physician assistants, and other health care professionals involved in the management of patients with non-small cell lung cancer (NSCLC).
Learning Objectives
Upon successful completion of the activity, participants should be better able to:
- Review the role of trophoblast cell surface antigen 2 (TROP2) in tumor biology as well as its implications as a cancer biomarker.
- Describe how novel antibody drug conjugates exploit TROP2 as an anticancer therapy.
- Examine current unmet needs for patients with NSCLC without actionable mutations.
- Assess the latest clinical safety and efficacy regarding new and emerging TROP2 antibody drug conjugates for the management of patients with NSCLC who have progressed on prior treatment.
Activity Description
For patients with non-small cell lung cancer (NSCLC) who do not have actionable genomic alterations, programmed death ligand 1 immunotherapy, with or without platinum-based chemotherapy, is the standard of care. These regimens have demonstrated clear clinical benefit, yet 40% to 60% of patients do not respond to these initial therapies, or eventually experience disease progression. Options are limited for these patients, but novel therapies, such as antibody drug conjugates that target trophoblast cell surface antigen 2 (TROP2), are currently under clinical investigation. TROP2 is expressed in approximately 70% of NSCLC tumors, and expression has been associated with poor outcomes. In this continuing medical education activity, experts in the field will review current unmet needs for patients with NSCLC without actionable mutations, discuss the role of TROP2 in tumor biology and its implications as a cancer biomarker, and assess the most recent clinical safety and efficacy data regarding new and emerging TROP2 antibody drug conjugates for the management of patients with NSCLC who have progressed on prior therapies.
Topic
- Introduction
- TROP2: Role in Tumor Biology and Implications for Biomarker (Jacob Sands, MD)
- Second-line Therapy for Patients With Non-Small Cell Lung Cancer: Unmet Needs (Benjamin P. Levy, MD)
- Advances in TROP2-Targeted Therapies for Patients With Non-Small Cell Lung Cancer (Rebecca Heist, MD)
- Conclusion by Activity Chair
Activity Chair
Physician, Dana-Farber Cancer Institute
Instructor of Medicine, Harvard Medical School
Boston, MA
Disclosure:
Consultant: AstraZeneca, Boehringer Ingelheim, Jazz Pharmaceuticals, Lilly, Takeda
Faculty
Associate Professor of Medicine
Harvard Medical School
Massachusetts General Hospital
Boston, MA
Disclosure:
Consultant: AbbVie, Daichii Sankyo, EMD Serono, Novartis
Independent Research Contractor (paid to institution): AbbVie, Agios, Corvus, Daichii Sankyo, Exelixis, Lilly, Mirati, Novartis, Turning Point
Associate Professor
Johns Hopkins School of Medicine
Washington, DC
Disclosure:
Consultant: AstraZeneca, Bristol Myers Squibb, Daiichi Sankyo, Janssen, Lilly, Merck, Pfizer
Reviewer
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.
Vindico Medical Education Staff
Disclosure: No relevant financial relationships to disclose.
Signed Disclosures are on file at Vindico Medical Education, Office
of Medical Affairs and Compliance.
Conflict of Interest Policy/Disclosure Statement
Vindico Medical Education adheres to the Accreditation Council for Continuing Medical Education’s (ACCME) Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers, or others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Accreditation Statement
Vindico Medical Education is accredited by the ACCME to provide continuing medical education for physicians.
Designation of Credit
Vindico Medical Education designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Successful
completion of this CME activity, which includes participation in the
evaluation component, enables the learner to satisfy the Lifelong Learning
requirements for the American Board of Pathology’s (ABPath) Continuing
Certification program and earn up to 1.0 CC points. It is the CME activity
provider’s responsibility to submit learner completion information to ACCME
for the purpose of granting Continuing Certification credit within
approximately 30 days.
Nurse practitioners can apply for AMA PRA Category 1 Credit(s)™ through the American Academy of Nurse Practitioners Certification Board (AANPCB). AANPCB will accept AMA PRA Category 1 Credit(s)™ from organizations accredited by ACCME.
American Academy of Physician Assistants (AAPA) accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit(s)™ from organizations accredited by the ACCME. Physician assistants may receive a maximum of 1.0 hours credit for completing this program.
This enduring material is approved for 1 year from the date of original release, March 31, 2022, to March 30, 2023.
Instructions for Receiving Credit
To participate in this CME activity, you must read the objectives, answer the pretest questions, view the CME content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 75% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.
Statement of Commercial Support
This activity is supported by an educational grant from Daiichi Sankyo, Inc.
Disclaimer Statement/Disclosure of Unlabeled Use
The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)–approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.
Copyright Statement
Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2022 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.
CME Questions?
Contact us at CME@VindicoCME.com